These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12738717)

  • 1. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
    Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
    Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
    Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
    Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
    Lara PN; Quinn DI; Margolin K; Meyers FJ; Longmate J; Frankel P; Mack PC; Turrell C; Valk P; Rao J; Buckley P; Wun T; Gosselin R; Galvin I; Gumerlock PH; Lenz HJ; Doroshow JH; Gandara DR;
    Clin Cancer Res; 2003 Oct; 9(13):4772-81. PubMed ID: 14581348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
    Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
    Cooney MM; Tserng KY; Makar V; McPeak RJ; Ingalls ST; Dowlati A; Overmoyer B; McCrae K; Ksenich P; Lavertu P; Ivy P; Hoppel CL; Remick S
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):295-300. PubMed ID: 15538570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
    Jennens RR; Rosenthal MA; Lindeman GJ; Michael M
    Urol Oncol; 2004; 22(3):193-6. PubMed ID: 15271314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
    Baker LH; Rowinsky EK; Mendelson D; Humerickhouse RA; Knight RA; Qian J; Carr RA; Gordon GB; Demetri GD
    J Clin Oncol; 2008 Dec; 26(34):5583-8. PubMed ID: 18981463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
    Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
    Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
    Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
    Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
    Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
    Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
    Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
    Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
    Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
    Stadler WM; Rosner G; Small E; Hollis D; Rini B; Zaentz SD; Mahoney J; Ratain MJ
    J Clin Oncol; 2005 Jun; 23(16):3726-32. PubMed ID: 15923569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
    Ebbinghaus S; Hussain M; Tannir N; Gordon M; Desai AA; Knight RA; Humerickhouse RA; Qian J; Gordon GB; Figlin R
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6689-95. PubMed ID: 18006769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.